AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
This piece covers Wash Sale Loss Carryforward Dividend ETF concepts, focusing on how losses carry forward and impact future trades.
12,804 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Insider sales by a bank CEO can raise questions. This article breaks down what a move like 'live bancshares sells ano...
A top exec recently sold a sizable block of Freshpet shares. This article breaks down what insider selling means, how...
A dividend-focused ETF is delivering outsized gains this year while offering steadier income. Learn how this dividend...
If you’re weighing SCHD as a core holding, this guide breaks down what the Schwab U.S. Dividend Equity ETF does, what...
A Sunrun co-founder disclosed the sale of 50,000 shares, prompting questions about timing and implications. This arti...
A sizable move in the First Trust QTEC fund has traders buzzing. Is the sale a warning sign for overheated AI stocks ...
A director sold a sizable chunk of World Kinect Corporation stock after a robust Q1.Is it a red flag or routine profi...
When a company’s founder and CEO sells a chunk of stock, investors want to know what it means for future performance....
If you’re hunting for reliable dividend income, AbbVie and Pfizer are two top contenders. This guide breaks down whic...
When a former chief officer sells stock, investors should look beyond the headline. This guide explains why insider m...
When a company's top executive sells a large chunk of stock, investors take note. This article dives into Privia Heal...